IPO - Edgewise Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-04-02

Corporate Action: Ipo

Type: New

Accession Number: 000110465925031266

Filing Summary: On April 2, 2025, Edgewise Therapeutics, Inc. filed a prospectus supplement related to a public offering of 9,935,419 shares of its common stock, with a par value of $0.0001 per share. The offering is priced at $20.13 per share, totaling approximately $200 million before underwriting discounts and commissions. The underwriters include Leerink Partners, Piper Sandler, Guggenheim Securities, and Truist Securities, expecting to deliver shares on April 3, 2025. Key advancements in their clinical pipeline include their leading candidate sevasemten for muscular dystrophies, supported by positive data from clinical trials and a recent Fast Track designation by the FDA for Duchenne muscular dystrophy. The document underscores risk factors associated with the investment and provides details about the use of proceeds from the offering, aimed at further developing their innovative treatments for severe muscle diseases. The company is located in Boulder, Colorado, and trades on the Nasdaq under the symbol 'EWTX'.

Document Link: View Document